Section Edited by Jason J. Luke, MD, FACP and Douglas G. McNeel, MD, PhD
Clinical trials: prospective studies including first-in-man clinical trials, phase II/III clinical studies, and immune monitoring investigations. Small, single institution-based retrospective reports are discouraged.
Preclinical studies: studies that lead to mechanistic understanding or novel development of agents and combination therapies directly relevant to human immunotherapy.
CDK5 destabilizes PD-L1 via chaperon-mediated autophagy to control cancer immune surveillance in hepatocellular carcinomaRuonan Zhang, Jie Wang, Yu Du, Ze Yu, Yihan Wang, Yixiao Jiang, Yixin Wu, Ting Le, Ziqi Li, Guoqiang Zhang, Lei Lv, Haijie Ma
24 November 2023
Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumorsMarkus Joerger, Emiliano Calvo, Heinz Laubli, Juanita Lopez, Guzmán Alonso, Elena Corral de la Fuente, Dagmar Hess, David König, Vicky Sanchez Perez, Christoph Bucher, Sangeeta Jethwa, Elena Garralda
21 November 2023
Polycomb repressor complex 2 suppresses interferon-responsive MHC-II expression in melanoma cells and is associated with anti-PD-1 resistanceJamaal L James, Brandie C Taylor, Margaret L Axelrod, Xiaopeng Sun, Lindsey N Guerin, Paula I Gonzalez-Ericsson, Yu Wang, Violeta Sanchez, Catherine C Fahey, Melinda E Sanders, Yaomin Xu, Emily Hodges, Douglas B Johnson, Justin M Balko
20 November 2023
Targeting the aryl hydrocarbon receptor (AhR) with BAY 2416964: a selective small molecule inhibitor for cancer immunotherapyChristina Kober, Julian Roewe, Norbert Schmees, Lars Roese, Ulrike Roehn, Benjamin Bader, Detlef Stoeckigt, Florian Prinz, Mátyás Gorjánácz, Helge Gottfried Roider, Catherine Olesch, Gabriele Leder, Horst Irlbacher, Ralf Lesche, Julien LefrancSee the full list of authors
14 November 2023
Systemic infusion of TLR3-ligand and IFN-α in patients with breast cancer reprograms local tumor microenvironments for selective CTL influxShipra Gandhi, Mateusz Opyrchal, Melissa J Grimm, Ronald T Slomba, Kathleen M Kokolus, Agnieszka Witkiewicz, Kristopher Attwood, Adrienne Groman, Lauren Williams, Mary Lynne Tarquini, Paul K Wallace, Kah Teong Soh, Hans Minderman, Orla Maguire, Tracey L O’ConnorSee the full list of authors
14 November 2023
MDR1-expressing CD4 T cells with Th1.17 features resist to neoadjuvant chemotherapy and are associated with breast cancer clinical responseAnthony Di Roio, Margaux Hubert, Laurie Besson, Marion Bossennec, Céline Rodriguez, Yenkel Grinberg-Bleyer, Guilhem Lalle, Lyvia Moudombi, Raphael Schneider, Cyril Degletagne, Isabelle Treilleux, Daniel J Campbell, Séverine Metzger, Thomas Duhen, Olivier TrédanSee the full list of authors
8 November 2023
Comprehensive analyses of immune tumor microenvironment in papillary renal cell carcinomaManon de Vries-Brilland, Nathalie Rioux-Leclercq, Maxime Meylan, Jonathan Dauvé, Christophe Passot, Elena Spirina-Menand, Ronan Flippot, Gaëlle Fromont, Gwenaelle Gravis, Lionnel Geoffrois, Christine Chevreau, Fréderic Rolland, Ellen Blanc, Félix Lefort, Alain RavaudSee the full list of authors
7 November 2023
Loss of ADAR1 in macrophages in combination with interferon gamma suppresses tumor growth by remodeling the tumor microenvironmentWeiwei Lin, Yikai Luo, Jie Wu, Haowan Zhang, Ge Jin, Chahua Guo, Hang Zhou, Han Liang, Xiaoyan Xu
7 November 2023
Th17-inducing dendritic cell vaccines stimulate effective CD4 T cell-dependent antitumor immunity in ovarian cancer that overcomes resistance to immune checkpoint blockadeYan Luo, Barath Shreeder, James W Jenkins, Huashan Shi, Purushottam Lamichhane, Kexun Zhou, Deborah A Bahr, Sophia Kurian, Katherine A Jones, Joshua I Daum, Navnita Dutta, Brian M Necela, Martin J Cannon, Matthew S Block, Keith L Knutson
2 November 2023
PER2 binding to HSP90 enhances immune response against oral squamous cell carcinoma by inhibiting IKK/NF-κB pathway and PD-L1 expressionZhiwei Zhang, Deping Sun, Hong Tang, Jie Ren, Shilin Yin, Kai Yang
1 November 2023